Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP- induced nigrostriatal dopamine depletions

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 1, 1997, Pages 100-107

  Fornai, Francesco ^a   Alessandrì, Maria Grazia ^a   Torracca, Maria Tilde ^a   Bassi, Lucia ^a   Corsini, Giovanni Umberto ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL METABOLIC RATE; BODY TEMPERATURE; BRAIN INJURY; CARDIOVASCULAR RESPONSE; CELL DAMAGE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; MOUSE; NERVE DEGENERATION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NORADRENALIN RELEASE; PARKINSON DISEASE; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; BENZYLAMINES; BRAIN; CORPUS STRIATUM; DOPAMINE; LOCUS COERULEUS; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NOREPINEPHRINE; SUBSTANTIA NIGRA;

EID: 0030831945     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. ALVORD, E. C. JR. AND FORNO, L. S.: Pathology. In Handbook of Parkinson's Disease, ed. by W. C. Koller, pp. 255-284, Marcel Dekker, New York, NY, 1992.
2. ANDÉN, N. AND GRABOWSKA, M.: Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain. Eur. J. Pharmacol. 39: 275-282, 1976.
3. BING, G., ZHANG, Y., WATANABE, Y., MCEWEN, B. S. AND STONE, E. A.: Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons in the substantia nigra. Brain Res. 668: 261-265, 1994.
4. + elimination in the mouse striatum. J. Pharmacol. Exp. Ther. 267: 1515-1520, 1993.
5. CHIBA, K., TREVOR, A. AND CASTAGNOLI, N. JR.: Metabolism of the neurotoxic tertiary amine. MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120: 574-578, 1984.
6. CORSINI, G. U., PINTUS, S., CHIUEH, C. C., WEISS, J. F. AND KOPIN, I. J.: 1-Methyl4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. Eur. J. Pharmacol. 119: 127-128, 1985.
7. FOLLESA, P. AND MOCCHETTI, I.: Regulation of basic fibroblast growth factor and nerve growth factor mRNA by beta-adrenergic receptor activation and adrenal steroids in rat central nervous system. Mol. Pharmacol. 43: 132-138, 1993.
8. FORNAI, F., ALESSANDRI, M. G., FASCETTI, F., VAGLINI, F. AND CORSINI, G. U.: Clonidine suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced reductions of striatal dopamine and tyrosine hydroxilase activity in mice. J. Neurochem. 65: 704-709, 1995a.
9. FORNAI, F., BASSI, L., TORRACCA, M. T., SCALORI, V. AND CORSINI, G. U.: Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur. J. Pharmacol. 283: 99-102, 1995b.
10. FORNAI, F., TORRACCA, M. T., BASSI, L., D'ERRIGO, D. A., SCALORI, V. AND CORSINI, G. U.: Norepinephrine loss selectively enhances chronic nigrostriatal dopamine depletion in mice and rats. Brain Res. 735: 349-353, 1996.
11. FORNAI, F., TORRACCA, M. T., BASSI, L., VAGLINI, F., MAGGIO, R. AND CORSINI, G. U.: Norepinephrine loss enhances methamphetamine-induced striatal dopamine depletion in mice and rats (Abstract). Soc. Neurosci. 21: 1245, 1995c.
12. GIOVANNI, A., SIEBER, B.-A., HEIKKILA, R. E. AND SONSALLA, P. K.: Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. J. Pharmacol. Exp. Ther. 270: 1000-1007, 1994a.
13. GIOVANNI, A., SONSALLA, P. K. AND HEIKKILA, R. E.: Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther. 270: 1008-1014, 1994b.
14. GRZANNA. R., BERGER, U., FRITSCHY, J. M. AND GEFFARD, M.: Acute action of DSP-4 on central norepinephrine axons: Biochemical and immunohistochemical evidence for differential effects. J. Histochem. Cytochem. 37: 1435-1442, 1989.
15. HEIKKILA, R. E., MANZINO, L., CABBAT, F. S. AND DUVOISIN, R. C.: Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-l,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature (Lond.) 311: 467-469, 1984.
16. + within the monoaminergic systems of the primate brain following MPTP administration: An in vivo autoradiographic study. Neuroscience 40: 133-158, 1991.
17. HORNYKIEWICZ, O. AND KISH, S. J.: Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45P: 19-34, 1987.
18. IRWIN, I., WU, E. Y., DELANNEY, L. E., TREVOR, A. AND LANGSTON, J. W.: The effect of diethyldithiocarbamate on the biodisposition of MPTP: An explanation for enhanced neurotoxicity. Eur. J. Pharmacol. 141: 209-217, 1987.
19. + by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin MPTP. Eur. J. Pharmacol. 106: 455-456, 1984.
20. JOHANNESSEN, J. N., CHIUEH, C. C., BURNS, R. S. AND MARKEY, S. P.: Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci. 36: 219-224, 1985.
21. JONSSON, G., HALLMAN, H., PONZIO, F. AND ROSS, S.: DSP-4 (N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine)-a useful denervation tool for central and peripheral noradrenaline neurons. Eur. J. Pharmacol. 72: 173-188, 1981.
22. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
23. MARIEN, M., BRILEY, M. AND COLPAERT, F.: Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur. J. Pharmacol. 236: 487-489, 1993.
24. MARKEY, S. P., JOHANNESSEN, J. N., CHIUEH, C. C., BURNS, R. S. AND HERKENHAM, M. A.: Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism. Nature (Lond.) 311: 464-467, 1984.
25. MAVRIDIS, M., DEGRYSE, A. D., LATEGAN, A. J., MARIEN, M. R. AND COLPAERT, F. C.: Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: A possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41: 507-523, 1991.
26. MASON, S. T. AND FIBIGER, H. C.: Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase. J. Comp. Neurol. 187: 703-724, 1979.
27. MIELE, M., ESPOSITO, G., MIGHELI, R., SIRCANA, S., ZANGANI, D., FRESU, G. L. AND DESOLE, M. S.: Effects of allopurinol on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurochemical changes in the striatum and in the brainstem of the rat. Neurosci. Lett. 183: 155-159, 1995.
28. OTTO, D. AND UNSICKER, K.: Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J. Neurosci. 10: 1912-1921, 1990.
29. PILEBLAD, E., NISSBRANDT, H. AND CARLSSON, A.: Biochemical and functional evidence for a marked dopamine releasing action of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (NMPTP) in mouse brain. J. Neural. Transm. 60: 199-203, 1984.
30. RIACHI, N. J., HARIK, S. I., KALARIA, R. N. AND SAYRE, L. M.: On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver. J. Pharmacol. Exp. Ther. 244: 443-448, 1988.
31. +). Naunyn Schmiedebergs Arch. Pharmacol. 346: 158-165, 1992.
32. TIPTON, K. F. AND SINGER, T. P.: Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61: 1191-1206, 1993.
33. + levels do not necessarily correlate with striatal dopamine levels after MPTP treatment. Neurodegeneration 5: 129-136, 1996.
34. + is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: A model for natural resistance to MPTP toxicity. Exp. Neurol. 127: 54-61, 1994.